{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T04:18:57Z","timestamp":1684988337827},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n            Objective Local treatments used in metastatic liver tumours efficiently control the disease and survival. Transarterial radioembolisation (TARE) is a safely used locoregional treatment method. We aim to investigate the impact of TARE on different kinds of metastatic liver tumours and the effect of pre-treatment clinical findings.<\/jats:p><jats:p>\n            Material and Methods The patients with metastatic liver tumours referred to our department for radioembolisation were retrospectively evaluated. All patients were given a Y-90 glass microsphere after being selected by the appropriate clinical and imaging criteria, lung shunt fraction levels, vascular investigation, and macro aggregated albumin (MAA) scintigraphy performed in the angiography unit.<\/jats:p><jats:p>\n            Results Thirty-four (17 women, 17 men) patients were suitable for the treatment. Patients were treated with 115.88\u00b147.84 Gy Y-90 glass Microspheres. The mean survival rate was 14.59\u00b112.59 months after treatment. Higher survival rates were detected in patients who had higher pre-treatment serum albumin levels. The optimum cut-off value of albumin to predict response to treatment was 4 g\/dl with 88.89% sensitivity, 62.50% specificity, 72.73% PPV and 83.33% NPV. Furthermore, one unit increase in age increased mortality 1.152 times in our patient group.<\/jats:p><jats:p>\n            Conclusion Radioembolisation is a safe and efficient method for controlling metastatic liver disease. Albumin levels significantly affect predicting response; higher albumin levels are related to higher survival rates. Furthermore, older age positively correlated with mortality rates in our patient group.<\/jats:p>","DOI":"10.1055\/a-2026-0851","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:10:37Z","timestamp":1677629437000},"page":"214-219","source":"Crossref","is-referenced-by-count":0,"title":["The value of radioembolisation therapy on metastatic liver tumours \u2013 a single centre experience"],"prefix":"10.1055","volume":"62","author":[{"given":"Ozgul","family":"Ekmekcioglu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Erdem","sequence":"additional","affiliation":[{"name":"Interventional Radiology Department, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelin","family":"Arican","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmet","family":"Ozvar","sequence":"additional","affiliation":[{"name":"Radiation Oncology, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgur","family":"Bostanci","sequence":"additional","affiliation":[{"name":"Hepatobiliary and General Surgery, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"ref1","first-page":"20","article-title":"New paradigm in the management of liver-only metastases from colorectal cancer","volume":"1","author":"M Donadon","year":"2007","journal-title":"Gastrointest Cancer Res: GCR"},{"key":"ref2","first-page":"2047981615570417","article-title":"A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma","volume":"4","author":"J Schelhorn","year":"2015","journal-title":"Acta Radiol Open"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.hpb.2016.06.010","article-title":"Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors","volume":"18","author":"I Sucandy","year":"2016","journal-title":"HPB: Off J Int Hepato Pancreato Biliary Assoc"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","article-title":"Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis","volume":"230","author":"ME Egger","year":"2020","journal-title":"J Am Coll Surg"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"100399","DOI":"10.1016\/j.ejro.2022.100399","article-title":"A prospective randomized trial comparing microwave and radiofrequency ablation for the treatment of liver metastases using a dual ablation system - The Mira study","volume":"9","author":"TJ Vogl","year":"2022","journal-title":"Eur J Radiol Open"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"E Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"AB Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hpb.12326","article-title":"\u201cRole of hepatic intraarterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference\u201d","volume":"17","author":"A Kennedy","year":"2015","journal-title":"Hpb"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolisation of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"M Lam","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00270-019-02366-8","article-title":"Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization","volume":"43","author":"AO Levey","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5152\/dir.2022.20911","article-title":"Interventional oncology procedures for breast cancer metastatic disease: current role and clinical applications","volume":"28","author":"DK Filippiadis","year":"2022","journal-title":"Diagn Interv Radiol"},{"key":"ref12","first-page":"274","article-title":"Radioembolization treatment for liver metastases","volume":"21","author":"J Kiszka\u0105","year":"2017","journal-title":"Contemp Oncol (Pozn)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/SLA.0b013e3181d3d24a","article-title":"Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases","volume":"251","author":"A Saxena","year":"2010","journal-title":"Ann Surg"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","article-title":"Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis","volume":"24","author":"S Mouli","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.tvir.2019.02.008","article-title":"Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease","volume":"22","author":"SA Padia","year":"2019","journal-title":"Tech Vasc Interv Radiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11547-010-0496-1","article-title":"Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases","volume":"115","author":"R Cianni","year":"2010","journal-title":"Radiol Med"},{"key":"ref17","first-page":"231","article-title":"Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience","volume":"41","author":"EM Trivi\u00f1o-Ib\u00e1\u00f1ez","year":"2022","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.21037\/jgo.2017.06.18","article-title":"Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolisation (TARE) for malignancies of the liver","volume":"8","author":"KP Orwat","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1245\/s10434-014-4164-x","article-title":"Is Yttrium- 90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single- center experience of 302 patients","volume":"22","author":"A Saxena","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00259-014-2799-2","article-title":"Twelve-year experience of radioembolisation for colorectal, hepatic metastases in 214 patients: survival by era and chemotherapy","volume":"41","author":"RJ Lewandowski","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2967\/jnumed.115.166082","article-title":"90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study","volume":"57","author":"R Hickey","year":"2016","journal-title":"J Nucl Med"},{"key":"ref22","first-page":"5104082","article-title":"Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases","author":"ES Tsang","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/548.6515","article-title":"Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study","volume":"96","author":"C Cao","year":"2010","journal-title":"Tumori"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000355821","article-title":"Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors","volume":"86","author":"M Michl","year":"2014","journal-title":"Oncology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s12885-016-2552-2","article-title":"Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single centre experience","volume":"16","author":"AY Kim","year":"2016","journal-title":"BMC Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jvir.2020.11.011","article-title":"Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study","volume":"32","author":"EA Lacayo","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"S Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2214\/AJR.10.4881","article-title":"Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience","volume":"196","author":"CF Gonsalves","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00270-012-0373-5","article-title":"Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients","volume":"36","author":"A Klingenstein","year":"2013","journal-title":"Cardiovasc Interv Radiol"}],"container-title":["Nuklearmedizin - NuclearMedicine"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2026-0851.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T23:38:25Z","timestamp":1684971505000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2026-0851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":29,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,5,24]]},"published-print":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2026-0851","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}